EURAP is a prospective observational study
of pregnancies with antiepileptic drugs
The well-being of women with epilepsy and their offspring is of great concern. Our aim is to contribute to a better understanding of the risks associated with antiepileptic drugs during pregnancy.
What we need is the collaboration of physicians from all corners of the world to join forces.
It was launched in Europe in 1999 by a consortium of independent research groups and later extended to several other nations worldwide. The aim was to collect data on the risk of antiepileptic drugs during pregnancy and share it in an international registry.
At present, physicians from 42 countries in Europe, Oceania, Asia, Latin America and Africa are actively collaborating, and more than 24,000 pregnancies have been registered.